-
Mashup Score: 0VJOncology – The video journal of oncology - 1 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1BET-Bromodomain and EZH2 Inhibitor Treated Chronic GVHD Mice - 2 year(s) ago
Zaiken MC, Flynn R, Paz KG, et al. BET-Bromodomain and EZH2 Inhibitor Treated Chronic GVHD Mice Have Blunted Germinal Centers With Distinct Transcriptomes. Blood. 2022; (doi: 10.1182/blood.2021014557). Anti-cancer enzyme inhibitors disrupt the germinal center (GC) in mice that is necessary for chronic graft-versus-host disease (cGVHD) to develop after allogeneic hematopoietic stem cell…
Source: ASTCT NucleusCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“Anti-cancer enzyme inhibitors disrupt the germinal center #GC in mice that is necessary for chronic graft-versus-host disease #cGVHD to develop after allogeneic hematopoietic stem cell transplant, making them promising therapeutic targets.” https://t.co/IJWQuEgu3s https://t.co/V6TOOTkciC
-
-
Mashup Score: 1Rutika Mehta, MD, MPH @rutikamehtaMD @MoffitNews @Moffi - 2 year(s) ago
Rutika Mehta, MD, MPH from Moffits Cancer Center. In this interview, Dr. Mehta speaks about the ASCO GI 2022 Abstract – A phase II study of TAS-102 (FTD/TP
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase II Study FTD/TPI Combined With RAM Rutika Mehta, MD, MPH @rutikamehtaMD @MoffitNews @MoffitResearch #ASCOGI22 #GC #GEJ #GEAs https://t.co/intERCzzpr https://t.co/rISqZy3Ipg
-
-
Mashup Score: 0Podcast Rutika Mehta, MD, MPH @rutikamehtaMD @MoffitNew - 2 year(s) ago
Rutika Mehta, MD, MPH, Medical Oncologist in Gastrointestinal Oncology at Moffitt Cancer Center. In this video, she speaks about the ASCO GI 2022 Abstract
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - Phase II Study FTD/TPI Combined With RAM Rutika Mehta, MD, MPH @rutikamehtaMD @MoffitNews @MoffitResearch #ASCOGI22 #GC #GEJ #GEAs Link to Audio: https://t.co/Bj2VdXJ8Dv https://t.co/j4M8ig5iZE
-
-
Mashup Score: 0Podcast Rutika Mehta, MD @rutikamehtaMD @MoffitNews @Mo - 2 year(s) ago
Rutika Mehta, MD, MPH, Medical Oncologist in Gastrointestinal Oncology at Moffitt Cancer Center. In this video, she speaks about the ASCO GI 2022 Abstract
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - Phase II RAINBOW Study Rutika Mehta, MD @rutikamehtaMD @MoffitNews @MoffitResearch #ASCOGI22 #GI22 #GC #GEJ #GEAs Link to Audio: https://t.co/Bj2VdXrxLX https://t.co/5pwv8ybA0q
-
-
Mashup Score: 0Rutika Mehta, MD @rutikamehtaMD @MoffitNews @MoffitRese - 2 year(s) ago
Rutika Mehta, MD, MPH, Medical Oncologist in Gastrointestinal Oncology at Moffitt Cancer Center. In this video, she speaks about the ASCO GI 2022 Abstract
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase II RAINBOW Study Rutika Mehta, MD @rutikamehtaMD @MoffitNews @MoffitResearch #ASCOGI22 #GI22 #GC #GEJ #GEAs https://t.co/B2leDdnEAA https://t.co/ytg6ryApRJ
-
-
Mashup Score: 11Yelena Janjigian, MD @YJanjigianMD @sloan_kettering @MS - 2 year(s) ago
Yelena Y. Janjigian, MD, Cheif, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. In this interview Dr. Janjigian speaks about t
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase II DESTINY-Gastric03 Study Yelena Janjigian, MD @YJanjigianMD @sloan_kettering @MSKCC #ASCOGI22 #GI22 #DESTINYGastric03 #GC #GEJA #Research https://t.co/ado3ZcC33H https://t.co/C5k2ySyGWS
-
-
Mashup Score: 14Podcast - Yelena Janjigian, MD @YJanjigianMD @sloan_ket - 2 year(s) ago
Yelena Y. Janjigian, MD, Cheif, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. In this interview Dr. Janjigian speaks about t
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - Phase II DESTINY-Gastric03 Study Yelena Janjigian, MD @YJanjigianMD @sloan_kettering @MSKCC #ASCOGI22 #GI22 #DESTINYGastric03 #GC #GEJA #Research Link to Audio: https://t.co/lr6zWAkTNS https://t.co/hD95f2rysV
-
-
Mashup Score: 0
Objective To unravel the dynamical trajectory and features of glucocorticoids (GC) tapering and discontinuation in patients with rheumatoid arthritis (RA) commencing GC with concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Methods We used data from longitudinal real-world Treat-to-TARget in RA cohort. Patients with RA who started GC and contaminant csDMARDs…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
Interested in #glucocorticoid discontinuation in #RA? Check out a recent study: ▶️median #GC dose reduced by 50% in 6 months and GC cessation in 27 months (median) ▶️50% patients in remission at GC discontinuation, >60% were flare-free within 6 months 🔗https://t.co/vFK3Bz1J7Y https://t.co/NTuqeIZn9N
-
It was great to catch up w/ @KoheiShitara who shared primary results from SPOTLIGHT evaluating zolbetuximab + mFOLFOX6 as 1L therapy in pts w/ Claudin-18.2 locally advanced gastric/GEJ Catch the full video soon on https://t.co/ys1d8pE8Am 👀 @ASCO #GI23 #GIsm #GastricCancer #GC https://t.co/Ode7UAU6bm